Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Herbalife Nutrition Ltd (HLF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Herbalife Nutrition Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while Herbalife Nutrition Ltd trades at $13.15 (market cap $1.36B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 29.3× Herbalife Nutrition Ltd's market cap, and Herbalife Nutrition Ltd is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | HLF | |
|---|---|---|
Market Cap | $39.89B | $1.36B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $19.96 |
52-Week Low | $278.09 | $7.75 |
Enterprise Value | $38.15B | $3.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Herbalife (HLF) trades at $13.15, up 1.94% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains stable revenue around $5B annually with improving debt metrics, though negative shareholder equity remains a concern. Recent Q1 2026 earnings beat expectations with EPS of $0.64 versus $0.607 expected, supported by strong international growth and successful $1.45B debt refinancing completed in April 2026.
HLF presents a value opportunity with low P/E (5.77) and P/S (0.27) ratios, but faces significant leverage risks and competitive pressures. Analyst sentiment leans bullish (58% buy ratings) despite technical weakness, with the stock's direction likely dependent on Q2 2026 results announcement scheduled for August 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →
